Precision oncology startup 4baseCare raises $6 million in funding

4baseCare, a Bengaluru-based healthcare startup focused on precision oncology, has raised $6 million in a Series A funding round led by Yali Capital, with participation from other investors.

The startup will use the raised capital to enhance its product offerings and scaling up operations for further expansion across India, as well as other countries in Asia and the Middle East. 

"This funding will further enable us to enhance our product offerings and advance our mission of making personalized cancer care accessible to millions," said Hitesh Goswami, CEO and Co-founder, 4baseCare.

Who are the founders?

Founded in 2018 by Hitesh Goswami and Kshitij Rishi, 4baseCare specialises in precision oncology through advanced genomics and digital health technologies.

The startup claims that its genomic tests have made a substantial impact across SouthEast Asia, benefiting over 10,000 cancer patients.

Its genomic-based tests include Indiegene which it claims is the world's first Indian population specific cancer gene panel for biomarker testing.

Establishing new genomics laboratories

The funding would also help 4baseCare to expand its reach by establishing new genomics laboratories in the Philippines, Nepal, and Dubai in the coming months. 

These efforts are part of the company’s broader strategy to improve clinical insights and provide data-driven treatment recommendations.

"4baseCare was founded with an aim to address the critical genomic data gap in cancer care. Our journey from developing TARGT Indiegene to impacting the lives of over 10,000 patients has been a very fulfilling experience. The success of our test and our growth over the years is a result of the exceptional support from our investors and the invaluable insights from our advisory board," Goswami said.

Investor comments

Mathew Cyriac, Founding General Partner, Yali Capital, said, "The genomics landscape in cancer care offers a tremendous opportunity to create impactful businesses while improving millions of lives. As a deep tech focused fund, we are particularly excited about 4baseCare's ability to enhance genomic tests with data from underrepresented populations, leading to improved treatment recommendations. 4baseCare has demonstrated impressive growth over the last few years, and we look forward to helping the team build a sustainable and profitable business."

4baseCare recently onboarded Francis deSouza, a former CEO of Illumina and a veteran of Silicon Valley, to its advisory board.

DeSouza brings over 30 years of experience in genomics, technology, and healthcare, providing invaluable insights that will guide 4baseCare’s future developments.